Boston Scientific Corporation develops and markets less invasive medical devices and therapies used by healthcare professionals and institutions globally. News about BSX centers on operating results, business highlights, capital-structure updates and product developments across cardiovascular, respiratory, digestive, oncological, neurological and urological care.
Recurring company updates include clinical evidence and regulatory milestones for platforms such as FARAPULSE pulsed field ablation, WATCHMAN left atrial appendage closure, EKOS endovascular therapy and the Asurys Fluid Management System. Coverage also reflects conference presentations, FDA clearances, trial results and management discussions of quarterly performance across the company’s medical-technology portfolio.
Blackstone (BX), through Blackstone Life Sciences, announced a $455 million collaboration with Boston Scientific to co-fund development of its VITALYST heart pump.
The VITALYST program is developing a temporary heart-support system intended to treat cardiogenic shock following a heart attack, when the heart cannot pump enough blood to supply vital organs with oxygen. Development goals include improving efficacy, safety and ease of use for treating physicians. This is the first collaboration in which Blackstone Life Sciences and Boston Scientific (NYSE: BSX) will co-fund development of a Boston Scientific product.
Boston Scientific (NYSE: BSX) announced that its SIMPLAAFY trial of the WATCHMAN FLX Pro device met its six-month primary endpoints. The randomized study enrolled 1,857 patients at 86 U.S. sites to compare single-drug regimens with dual anti-platelet therapy (DAPT) after implantation in patients with non-valvular atrial fibrillation.
Aspirin alone and a reduced-dose anticoagulant regimen each achieved noninferiority, meaning they met the trial's criteria for being no worse than DAPT. Both showed less bleeding and equivalent ischemic stroke rates of 0.7%. At 45 days, device-related clotting was 0.9% versus 3.4% with reduced-dose anticoagulant versus DAPT (P=0.01). The single-drug regimens remain investigational. Follow-up will continue through 12 months. Results were presented at TCT 2026 and simultaneously published in JAMA.
Penumbra (NYSE: PEN) reported third-quarter 2026 revenue of $410.1 million, up 15.6% from the same quarter a year earlier. Thrombectomy revenue rose 18.1% to $279.2 million, while embolization and access revenue increased 10.8% to $131.0 million. Gross margin reached 68.3%, versus 67.8% a year earlier.
Operating income increased to $50.739 million from $48.838 million, but net income fell to $42.279 million from $45.851 million. Diluted earnings per share declined to $1.07 from $1.17. Operating expenses rose to $229.564 million from $191.578 million, including $7.1 million in acquisition-related expenses. Penumbra said its pending acquisition by Boston Scientific (NYSE: BSX) is the reason it will not provide full-year 2026 guidance or host a quarterly results call. Nine-month revenue rose 15.4% to $1.175 billion, while net income fell to $109.674 million from $130.344 million.
Boston Scientific (BSX) reported third-quarter 2026 net sales of $5.138 billion, up 1.5 percent from the prior-year quarter. GAAP net income attributable to common stockholders fell to $582 million, or $0.40 per share, from $755 million, or $0.51 per share. Adjusted earnings per share fell to $0.73 from $0.75. MedSurg sales rose 0.6 percent and Cardiovascular sales rose 1.9 percent on a reported basis.
The company expects full-year reported sales growth of approximately 4.25 percent and adjusted earnings per share of $3.16 to $3.18. For the fourth quarter, it expects reported and organic sales declines of approximately 3.0 to 1.0 percent and adjusted earnings per share of $0.77 to $0.79. Boston Scientific also began enrollment in the Elite AF trial and received FDA clearances for two StoneSmart technologies and expanded SEISMIQ catheter sizes.
Boston Scientific (NYSE: BSX) will participate in Stifel's 2026 Healthcare Conference on November 11, 2026, with a question-and-answer session.
Kenneth Stein, chief medical officer, and Lance Bates, president of Interventional Cardiology & Vascular Therapies, will join the 30-minute session at approximately 8:00 a.m. ET. A live webcast will be available on the investor website, with a replay approximately one hour after the event ends.
Boston Scientific (NYSE: BSX) appointed Joseph M. Fitzgerald executive vice president and chief operating officer, effective Jan. 1, 2027.
Fitzgerald will oversee global operations, business units and regions. On the same date, the company will establish three reportable segments: Interventional Therapies, Rhythm Solutions and MedSurg. Boston Scientific says the structure is designed to enable faster decisions and support investment allocation across its portfolio. Lance Bates, Nick Spadea-Anello and Stephen Morse will lead the respective segments and report to Fitzgerald. Interventional Therapies will include Penumbra following the anticipated close of its acquisition. Fitzgerald currently serves as executive vice president and group president, Cardiovascular.
Elutia (Nasdaq: ELUT) received the full $8 million escrow payment from Boston Scientific following the sale of its BioEnvelope business. The payment followed an indemnity holdback period beginning with the October 1, 2025 closing of the $88 million transaction. Boston Scientific released the funds on schedule, with no claims.
The payment completes all three funding milestones outlined in Elutia’s second-quarter earnings release. Its Avenue Capital loan facility closed on August 11, 2026, and its SimpliDerm divestiture closed on August 17, 2026. Elutia believes it is now funded into 2029 and continues to expect a favorable FDA clearance decision for NXT-41x in the first half of 2027. NXT-41x is an antibiotic-releasing surgical matrix being developed for plastic and reconstructive surgery; FDA clearance remains pending.
Boston Scientific (NYSE: BSX) plans to participate in the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, featuring a 35-minute Q&A session with its CEO Mike Mahoney and CMO Kenneth Stein at approximately 8:00 a.m. ET.
The company will also host a third quarter 2026 earnings conference call on October 28, 2026 at 8:00 a.m. ET, led by Mike Mahoney and CFO Jon Monson, following a same-day earnings news release. Live webcasts and replays for both events will be available on the Boston Scientific investor relations website about one hour after each event concludes.
Penumbra (NYSE: PEN) reported second-quarter 2026 revenue of $390.0 million, up 14.9% year over year. Thrombectomy revenue was $259.0 million (+12.5%), while embolization and access revenue reached $131.1 million (+20.0%). U.S. revenue grew 17.1% to $305.4 million; international revenue increased 7.6% to $84.6 million.
Gross margin was 67.9%, up 1.9 percentage points. Operating expenses were $223.9 million, including $6.9 million of acquisition-related costs tied to the pending acquisition by Boston Scientific (NYSE: BSX). Income from operations was $41.0 million, and net income was $34.8 million, or $0.88 diluted EPS. Penumbra will not provide 2026 guidance or host a Q2 earnings call due to the pending transaction.
Boston Scientific (NYSE: BSX) reported Q2 2026 net sales of $5.442 billion, up 7.5% reported and 7.0% operational and organic versus Q2 2025. GAAP EPS was $0.61 (vs. $0.53), and adjusted EPS reached $0.86, above the $0.82–$0.84 guidance range.
MedSurg sales grew 5.9% and Cardiovascular 8.3% reported. By region, U.S. rose 6.2%, EMEA 6.1%, APAC 11.2% and LACA 22.4% reported. Operating income increased to $1.178 billion from $819 million, while litigation-related net charges were $76 million.
The company completed a $2 billion accelerated share repurchase (~40 million shares) and invested $1.5 billion for a 34% stake in MiRus and an exclusive option on its TAVR business. Boston Scientific also highlighted positive clinical data for FARAPULSE and SEISMIQ technologies and received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter. Full-year 2026 guidance is for net sales growth of 5.5–6.5% reported and adjusted EPS of $3.28–$3.32; Q3 2026 net sales growth is guided to 3–5% with adjusted EPS of $0.80–$0.82.